Filing Flows › Immunocore Holdings (IMCR) › Q3 2026 › vs Q3 2025
Immunocore Holdings (IMCR) Q3 2026 vs Q3 2025 (year over year)
Immunocore Holdings's revenue fell $1.5M (-1%) from $104M in Q3 2025 to $102M in Q3 2026.
Immunocore Holdings, Q3 2026: revenue $102M (-1% year over year), operating margin -13.3%, net loss $14.2M, operating cash flow $20.1M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 17.4% | -5.0% | +22.4 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $102M | $104M | −$1.5M | -1% |
| Net loss | $14.2M | $177K | $14.0M | 80× |
| Costs & expenses | $116M | $111M | $5.1M | +5% |
| Operating costs | $116M | $111M | $5.0M | +4% |
| Interest & other, net | $460K | −$7.5M | $7.9M | — |
| Income tax | $153K | $481K | −$328K | -68% |
| Cost of revenue | $676K | $513K | $163K | +32% |
| Research & development | $74.7M | $70.6M | $4.1M | +6% |
| SG&A | $40.5M | $39.8M | $673K | +2% |
| Operating cash sources | $34.3M | −$4.3M | $38.6M | — |
| Depreciation | $1.1M | $798K | $308K | +39% |
| Share-based compensation | $9.7M | $9.8M | −$107K | -1% |
| Working capital & other | $23.5M | −$14.9M | $38.4M | — |
| Net loss absorbed | $14.2M | $177K | $14.0M | 80× |
| Operating cash flow | $20.1M | −$4.5M | $24.5M | — |
| Free cash flow (OCF − capex) | $17.7M | −$5.2M | $22.9M | — |
| Capital expenditures | $2.3M | $748K | $1.6M | +214% |
Questions
How much did Immunocore Holdings's revenue grow year over year in Q3 2026?
Immunocore Holdings's revenue fell $1.5M (-1%) from $104M in Q3 2025 to $102M in Q3 2026.